US › Healthcare

Kyntra Bio, Inc. (KYNB)

US · Healthcare · Biotechnology

$7.10-6.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$-1.5M

Revenue YoY

-209.3%

Net profit

$12.0M

EPS

$-4.68

EPS estimate

$-3.18

EPS came in at -4.68 against a street estimate of -3.18 — a miss of 47.2%.

Key statistics

Market cap

$30.8M

Forward P/E

61.3

P/B

80.40

Book value

$-7.45

EPS (TTM)

$-7.51

52-week high

$12.58

52-week low

$6.32

50-day MA

$7.44

200-day MA

$7.57

Beta

1.06

Analyst view

with an average price target of $39.00.

Shareholding

Insiders

2.02%

Institutions

24.68%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.88%
Vanguard Capital Management, LLC	3.87%
Acadian Asset Management LLC	2.61%
BlackRock Inc	2.08%
Two Sigma Investments LLC	1.22%
Geode Capital Management, LLC	1.14%
HighTower Advisors, LLC	0.98%
UBS Group AG	0.68%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kyntra Bio, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.